Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Up 212.5% in April

Avenue Therapeutics, Inc. (NASDAQ:ATXIGet Rating) was the recipient of a large increase in short interest during the month of April. As of April 30th, there was short interest totalling 82,800 shares, an increase of 212.5% from the April 15th total of 26,500 shares. Currently, 0.8% of the company’s shares are short sold. Based on an average trading volume of 4,880,000 shares, the short-interest ratio is presently 0.0 days.

Several hedge funds have recently added to or reduced their stakes in ATXI. Citadel Advisors LLC purchased a new stake in shares of Avenue Therapeutics during the third quarter worth about $41,000. Goldman Sachs Group Inc. increased its stake in shares of Avenue Therapeutics by 34.1% during the second quarter. Goldman Sachs Group Inc. now owns 23,224 shares of the company’s stock worth $58,000 after purchasing an additional 5,905 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Avenue Therapeutics by 50.8% during the third quarter. Renaissance Technologies LLC now owns 118,100 shares of the company’s stock worth $176,000 after purchasing an additional 39,786 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in shares of Avenue Therapeutics during the second quarter worth about $183,000. 10.87% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:ATXI traded up $0.01 during trading on Friday, reaching $0.34. The company’s stock had a trading volume of 180,208 shares, compared to its average volume of 305,940. The firm’s 50 day simple moving average is $0.50 and its two-hundred day simple moving average is $0.81. Avenue Therapeutics has a 12 month low of $0.20 and a 12 month high of $5.19.

Avenue Therapeutics Company Profile (Get Rating)

Avenue Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain.

See Also

Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.